SEP 7, 2026 · JOURNAL ARTICLE
Efficacy and Safety of Savolitinib Plus Osimertinib in EGFR-Mutant, MET-Aberrant Advanced Non–Small Cell Lung Cancer
American Journal of Clinical Oncology
Meta-analysis of single-arm cohorts showing encouraging efficacy (ORR 53.9%) and manageable safety, but limited by lack of randomized comparator and reliance on surrogate endpoints; requires confirmatory RCT evidence.
Reported
Primary endpoint (ORR)53.9%
95% CI for ORR45.1–62.4
Disease control rate85.2%